Barclays
NAMS icon

Barclays’s NewAmsterdam Pharma NAMS Stock Holding History

Barclays’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$274K Sell
8,072
-13,708
-63% -$452K ﹤0.01% 3538
2026
Q1 		$697K Buy
21,780
+16,128
+285% +$525K ﹤0.01% 2978
2025
Q4 		$198K Sell
5,652
-66
-1% -$2.4K ﹤0.01% 4325
2025
Q3 		$163K Sell
5,718
-12,153
-68% -$291K ﹤0.01% 4419
2025
Q2 		$324K Buy
17,871
+1,986
+13% +$36.2K ﹤0.01% 4010
2025
Q1 		$325K Sell
15,885
-828
-5% -$18.4K ﹤0.01% 3782
2024
Q4 		$430K Buy
16,713
+9,117
+120% +$194K ﹤0.01% 3922
2024
Q3 		$126K Buy
7,596
+7,199
+1,813% +$125K ﹤0.01% 4508
2024
Q2 		$7.63K Buy
397
+303
+322% +$6.08K ﹤0.01% 4543
2024
Q1 		$2.22K Sell
94
-419
-82% -$8.5K ﹤0.01% 4911
2023
Q4 		$5.73K Hold
513
– – ﹤0.01% 5021
2023
Q3 		$4.75K Buy
+513
New +$5.55K ﹤0.01% 4391

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Barclays's NAMS Position: Q2 2026 in Review

Barclays reduced its NewAmsterdam Pharma (NAMS) stake by 63% in Q2 2026, selling an estimated $452K and leaving 8,072 shares worth $274K. The position accounts for ﹤0.01% of the portfolio, ranked #3538.

Barclays first reported a position in NAMS in Q3 2023 and has held it in 12 quarters since. The position peaked at $697K in Q1 2026. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Barclays held 8,072 shares of NewAmsterdam Pharma worth $274K as of Q2 2026.
  • Barclays sold 13,708 NewAmsterdam Pharma shares in Q2 2026, an estimated $452K.
  • NewAmsterdam Pharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3538 holding.
  • Barclays first reported a position in NewAmsterdam Pharma in Q3 2023 and has held it in 12 quarters since.
  • Barclays's NewAmsterdam Pharma position peaked at $697K in Q1 2026.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.